134 related articles for article (PubMed ID: 15724801)
41. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism.
Lakryc EM; Motta EL; Soares JM; Haidar MA; de Lima GR; Baracat EC
Gynecol Endocrinol; 2003 Feb; 17(1):57-63. PubMed ID: 12724020
[TBL] [Abstract][Full Text] [Related]
42. Impaired pregnenolone secretion after combined cyproterone acetate and ethynyl estradiol therapy in hirsute patients.
Inaudi P; D'Ambrogio G; Massafra C; Facchini V; Genazzani AR
Gynecol Obstet Invest; 1982; 14(2):106-20. PubMed ID: 6288518
[TBL] [Abstract][Full Text] [Related]
43. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.
Carmina E; Lobo RA
Obstet Gynecol; 1991 Nov; 78(5 Pt 1):845-9. PubMed ID: 1833685
[TBL] [Abstract][Full Text] [Related]
44. The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women.
Marcondes JA; Minanni SL; Luthold WW; Lerário AC; Nery M; Mendonça BB; Wajchenberg BL; Kirschner MA
J Endocrinol Invest; 1995 Jun; 18(6):431-5. PubMed ID: 7594237
[TBL] [Abstract][Full Text] [Related]
45. Antiandrogens and hirsutism.
Biffignandi P; Molinatti GM
Horm Res; 1987; 28(2-4):242-9. PubMed ID: 2969862
[TBL] [Abstract][Full Text] [Related]
46. Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism.
Chapman MG; Dowsett M; Dewhurst CJ; Jeffcoate SL
Br J Obstet Gynaecol; 1985 Sep; 92(9):983-5. PubMed ID: 4041402
[TBL] [Abstract][Full Text] [Related]
47. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
[TBL] [Abstract][Full Text] [Related]
48. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
Alpañés M; Álvarez-Blasco F; Fernández-Durán E; Luque-Ramírez M; Escobar-Morreale HF
Eur J Endocrinol; 2017 Nov; 177(5):399-408. PubMed ID: 28912358
[TBL] [Abstract][Full Text] [Related]
49. Prolonged suppression of hirsutism with combination therapy in an adolescent with insulin resistance and acanthosis nigricans.
Moore DC
J Adolesc Health Care; 1987 Sep; 8(5):445-8. PubMed ID: 3667400
[TBL] [Abstract][Full Text] [Related]
50. Pharmacodynamic studies on desogestrel administered alone and in combination with ethinylestradiol.
Cullberg G
Acta Obstet Gynecol Scand Suppl; 1985; 133():1-30. PubMed ID: 3161265
[TBL] [Abstract][Full Text] [Related]
51. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease.
Ciotta L; Cianci A; Giuffrida G; Marletta E; Aglianò A; Palumbo G
Fertil Steril; 1996 Jan; 65(1):61-7. PubMed ID: 8557156
[TBL] [Abstract][Full Text] [Related]
52. Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome.
Hagag P; Steinschneider M; Weiss M
J Reprod Med; 2014; 59(9-10):455-63. PubMed ID: 25330687
[TBL] [Abstract][Full Text] [Related]
53. The Hirsute woman: challenges in evaluation and management.
Paparodis R; Dunaif A
Endocr Pract; 2011; 17(5):807-18. PubMed ID: 21856600
[TBL] [Abstract][Full Text] [Related]
54. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
O'Brien RC; Cooper ME; Murray RM; Seeman E; Thomas AK; Jerums G
J Clin Endocrinol Metab; 1991 May; 72(5):1008-13. PubMed ID: 1827125
[TBL] [Abstract][Full Text] [Related]
55. Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with polycystic ovarian syndrome.
Matteri RK; Stanczyk FZ; Gentzschein EE; Delgado C; Lobo RA
Am J Obstet Gynecol; 1989 Dec; 161(6 Pt 1):1704-9. PubMed ID: 2532471
[TBL] [Abstract][Full Text] [Related]
56. Serum prostate-specific antigen concentration is increased in acromegalic women.
Manetti L; Lupi I; Genovesi M; Morselli L; Grasso L; Nencetti C; Gasperi M; Bogazzi F; Bartalena L; Martino E
J Endocrinol Invest; 2004; 27(7):643-7. PubMed ID: 15505987
[TBL] [Abstract][Full Text] [Related]
57. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism.
Lumachi F; Rondinone R
Fertil Steril; 2003 Apr; 79(4):942-6. PubMed ID: 12749435
[TBL] [Abstract][Full Text] [Related]
58. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
Maier PS; Mattiello SS; Lages L; Spritzer PM
Gynecol Endocrinol; 2012 Aug; 28(8):606-10. PubMed ID: 22329763
[TBL] [Abstract][Full Text] [Related]
59. A novel use of spironolactone: treatment of hirsutism.
Shapiro G; Evron S
J Clin Endocrinol Metab; 1980 Sep; 51(3):429-32. PubMed ID: 7410528
[TBL] [Abstract][Full Text] [Related]
60. Increased free testosterone but normal 5 alpha-reduced testosterone metabolites in obese premenopausal women.
Giagulli VA; De Pergola G; Giorgino F; Cignarelli M; Abbaticchio G; Vermeulen A; Giorgino R
Clin Endocrinol (Oxf); 1992 Jun; 36(6):553-8. PubMed ID: 1424180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
